Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. [electronic resource]
Producer: 20131105Description: 1510-7 p. digitalISSN:- 1528-0020
- Adrenal Cortex Hormones -- therapeutic use
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- B-Cell Activating Factor -- immunology
- Disease-Free Survival
- Female
- Graft vs Host Disease -- prevention & control
- Humans
- Male
- Middle Aged
- Peripheral Blood Stem Cell Transplantation -- adverse effects
- Prospective Studies
- Rituximab
- Transplantation, Homologous
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.